Walter J. Storkus - Publications

Affiliations: 
University of Pittsburgh, Pittsburgh, PA, United States 
Area:
Cell Biology, Microbiology Biology

68 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Weinstein AM, Chen L, Brzana EA, Patil PR, Taylor JL, Fabian KL, Wallace CT, Jones SD, Watkins SC, Lu B, Stroncek DF, Denning TL, Fu YX, Cohen PA, Storkus WJ. Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment. Oncoimmunology. 6: e1322238. PMID 28680760 DOI: 10.1080/2162402X.2017.1322238  0.52
2017 Vujanovic L, Stahl EC, Pardee AD, Geller DA, Tsung A, Watkins SC, Gibson GA, Storkus WJ, Butterfield LH. Tumor-derived α-fetoprotein directly drives human natural killer cell activation and subsequent cell death. Cancer Immunology Research. PMID 28468916 DOI: 10.1158/2326-6066.CIR-16-0216  0.76
2017 Fabian KP, Chi-Sabins N, Taylor JL, Fecek R, Weinstein A, Storkus WJ. Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice. Oncoimmunology. 6: e1290035. PMID 28405524 DOI: 10.1080/2162402X.2017.1290035  0.52
2016 Weinstein AM, Storkus WJ. Biosynthesis and Functional Significance of Peripheral Node Addressin in Cancer-Associated TLO. Frontiers in Immunology. 7: 301. PMID 27555845 DOI: 10.3389/fimmu.2016.00301  0.52
2016 Ghosh T, Barik S, Bhuniya A, Dhar J, Dasgupta S, Ghosh S, Sarkar M, Guha I, Sarkar K, Chakrabarti P, Saha B, Storkus WJ, Baral R, Bose A. Tumor-associated mesenchymal stem cells inhibit naïve T cell expansion by blocking cysteine export from dendritic cells. International Journal of Cancer. PMID 27405489 DOI: 10.1002/ijc.30265  0.48
2015 Zhang Y, Chen G, Liu Z, Tian S, Zhang J, Carey CD, Murphy KM, Storkus WJ, Falo LD, You Z. Genetic Vaccines To Potentiate the Effective CD103+ Dendritic Cell-Mediated Cross-Priming of Antitumor Immunity. Journal of Immunology (Baltimore, Md. : 1950). 194: 5937-47. PMID 25972487 DOI: 10.4049/jimmunol.1500089  0.52
2014 Wesa AK, Mandic M, Taylor JL, Moschos S, Kirkwood JM, Kwok WW, Finke JH, Storkus WJ. Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients. Frontiers in Oncology. 4: 266. PMID 25325015 DOI: 10.3389/fonc.2014.00266  0.76
2014 Lowe DB, Taylor JL, Storkus WJ. Monitoring antigen-specific T cell responses using real-time PCR. Methods in Molecular Biology (Clifton, N.J.). 1186: 65-74. PMID 25149303 DOI: 10.1007/978-1-4939-1158-5_5  0.56
2014 Lowe DB, Bose A, Taylor JL, Tawbi H, Lin Y, Kirkwood JM, Storkus WJ. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology. 3: e27589. PMID 24734217 DOI: 10.4161/onci.27589  0.52
2013 Chen L, Fabian KL, Taylor JL, Storkus WJ. Therapeutic use of dendritic cells to promote the extranodal priming of anti-tumor immunity. Frontiers in Immunology. 4: 388. PMID 24348473 DOI: 10.3389/fimmu.2013.00388  0.52
2013 Chi Sabins N, Taylor JL, Fabian KP, Appleman LJ, Maranchie JK, Stolz DB, Storkus WJ. DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1958-68. PMID 23896726 DOI: 10.1038/mt.2013.133  0.52
2013 Bose A, Barik S, Banerjee S, Ghosh T, Mallick A, Bhattacharyya Majumdar S, Goswami KK, Bhuniya A, Banerjee S, Baral R, Storkus WJ, Dasgupta PS, Majumdar S. Tumor-derived vascular pericytes anergize Th cells. Journal of Immunology (Baltimore, Md. : 1950). 191: 971-81. PMID 23785117 DOI: 10.4049/jimmunol.1300280  0.48
2013 Janelsins BM, Sumpter TL, Tkacheva OA, Rojas-Canales DM, Erdos G, Mathers AR, Shufesky WJ, Storkus WJ, Falo LD, Morelli AE, Larregina AT. Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12. Blood. 121: 2923-33. PMID 23365459 DOI: 10.1182/blood-2012-07-446054  0.52
2012 Rao A, Lowe DB, Storkus WJ. Shock block for improved immunotherapy. Oncoimmunology. 1: 1427-1429. PMID 23243617 DOI: 10.4161/onci.21174  0.56
2012 Cohen PA, Ko JS, Storkus WJ, Spencer CD, Bradley JM, Gorman JE, McCurry DB, Zorro-Manrique S, Dominguez AL, Pathangey LB, Rayman PA, Rini BI, Gendler SJ, Finke JH. Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. Immunological Investigations. 41: 680-710. PMID 23017141 DOI: 10.3109/08820139.2012.703745  0.52
2012 Rao A, Taylor JL, Chi-Sabins N, Kawabe M, Gooding WE, Storkus WJ. Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. Cancer Research. 72: 3196-206. PMID 22552283 DOI: 10.1158/0008-5472.CAN-12-0538  0.52
2012 Bose A, Lowe DB, Rao A, Storkus WJ. Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Research. 22: 236-43. PMID 22504156 DOI: 10.1097/CMR.0b013e3283538293  0.56
2012 Zhao X, Bose A, Komita H, Taylor JL, Chi N, Lowe DB, Okada H, Cao Y, Mukhopadhyay D, Cohen PA, Storkus WJ. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 188: 1782-8. PMID 22246626 DOI: 10.4049/jimmunol.1101644  0.52
2012 Qu Y, Chen L, Lowe DB, Storkus WJ, Taylor JL. Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 644-51. PMID 22215017 DOI: 10.1038/mt.2011.283  0.52
2011 Lowe DB, Storkus WJ. Chronic inflammation and immunologic-based constraints in malignant disease. Immunotherapy. 3: 1265-74. PMID 21995576 DOI: 10.2217/imt.11.113  0.56
2011 Zhao X, Bose A, Komita H, Taylor JL, Kawabe M, Chi N, Spokas L, Lowe DB, Goldbach C, Alber S, Watkins SC, Butterfield LH, Kalinski P, Kirkwood JM, Storkus WJ. Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 805-14. PMID 21189473 DOI: 10.1038/mt.2010.295  0.56
2011 Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, Ko JS, Cohen PA, Finke JH, Storkus WJ. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. International Journal of Cancer. Journal International Du Cancer. 129: 2158-70. PMID 21170961 DOI: 10.1002/ijc.25863  0.52
2010 Pardee AD, McCurry D, Alber S, Hu P, Epstein AL, Storkus WJ. A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Research. 70: 9041-52. PMID 21045144 DOI: 10.1158/0008-5472.CAN-10-1369  0.76
2010 Qu Y, Chen L, Pardee AD, Taylor JL, Wesa AK, Storkus WJ. Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment. Journal of Immunology (Baltimore, Md. : 1950). 185: 2895-902. PMID 20675595 DOI: 10.4049/jimmunol.1001294  0.76
2010 Lipscomb MW, Taylor JL, Goldbach CJ, Watkins SC, Wesa AK, Storkus WJ. DC expressing transgene Foxp3 are regulatory APC. European Journal of Immunology. 40: 480-93. PMID 19941313 DOI: 10.1002/eji.200939667  0.76
2009 Pardee AD, Wesa AK, Storkus WJ. Integrating costimulatory agonists to optimize immune-based cancer therapies. Immunotherapy. 1: 249-64. PMID 20046961 DOI: 10.2217/1750743X.1.2.249  0.76
2009 Lipscomb MW, Chen L, Taylor JL, Goldbach C, Watkins SC, Kalinski P, Butterfield LH, Wesa AK, Storkus WJ. Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro. Journal of Immunology (Baltimore, Md. : 1950). 183: 7250-8. PMID 19915058 DOI: 10.4049/jimmunol.0901477  0.76
2009 Sasaki K, Pardee AD, Qu Y, Zhao X, Ueda R, Kohanbash G, Bailey LM, Okada H, Muthuswamy R, Kalinski P, Basse PH, Falo LD, Storkus WJ. IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. Journal of Immunotherapy (Hagerstown, Md. : 1997). 32: 793-802. PMID 19752754 DOI: 10.1097/CJI.0b013e3181acec1e  0.52
2009 Kawabe M, Mandic M, Taylor JL, Vasquez CA, Wesa AK, Neckers LM, Storkus WJ. Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells. Cancer Research. 69: 6995-7003. PMID 19690146 DOI: 10.1158/0008-5472.CAN-08-4511  0.52
2009 Komita H, Zhao X, Katakam AK, Kumar P, Kawabe M, Okada H, Braughler JM, Storkus WJ. Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity. Cancer Gene Therapy. 16: 883-91. PMID 19444303 DOI: 10.1038/cgt.2009.33  0.52
2008 Wesa AK, Herrem CJ, Mandic M, Taylor JL, Vasquez C, Kawabe M, Tatsumi T, Leibowitz MS, Finke JH, Bukowski RM, Bruckheimer E, Kinch MS, Storkus WJ. Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. Journal of Immunology (Baltimore, Md. : 1950). 181: 7721-7. PMID 19017961  0.52
2008 Sasaki K, Pardee AD, Okada H, Storkus WJ. IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit. European Journal of Immunology. 38: 2865-73. PMID 18958887 DOI: 10.1002/eji.200838334  0.76
2008 Komita H, Zhao X, Taylor JL, Sparvero LJ, Amoscato AA, Alber S, Watkins SC, Pardee AD, Wesa AK, Storkus WJ. CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth. Cancer Research. 68: 8076-84. PMID 18829566 DOI: 10.1158/0008-5472.CAN-08-0387  0.76
2008 Sasaki K, Zhao X, Pardee AD, Ueda R, Fujita M, Sehra S, Kaplan MH, Kane LP, Okada H, Storkus WJ. Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo. Journal of Immunology (Baltimore, Md. : 1950). 181: 104-8. PMID 18566374  0.76
2008 Moschos SJ, Mandic M, Kirkwood JM, Storkus WJ, Lotze MT. Focus on FOCIS: Interleukin 2 treatment associated autoimmunity Clinical Immunology. 127: 123-129. PMID 18405863 DOI: 10.1016/j.clim.2008.02.011  0.52
2008 Gigante M, Mandic M, Wesa AK, Cavalcanti E, Dambrosio M, Mancini V, Battaglia M, Gesualdo L, Storkus WJ, Ranieri E. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. Journal of Immunotherapy (Hagerstown, Md. : 1997). 31: 254-62. PMID 18317362 DOI: 10.1097/CJI.0b013e318167b023  0.52
2007 Storkus WJ, Herrem C, Kawabe M, Cohen PA, Bukowski RM, Finke JH, Wesa AK. Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes. Critical Reviews in Immunology. 27: 485-93. PMID 18197809  0.52
2007 Vujanovic L, Mandic M, Olson WC, Kirkwood J, Storkus WJ. A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6 Clinical Cancer Research. 13: 6796-6806. PMID 18006782 DOI: 10.1158/1078-0432.CCR-07-1909  0.52
2007 Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ, Okada H, et al. Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Research. 67: 10012-8. PMID 17942935 DOI: 10.1158/0008-5472.CAN-07-1735  0.52
2007 Sasaki K, Zhu X, Vasquez C, Nishimura F, Dusak JE, Huang J, Fujita M, Wesa A, Potter DM, Walker PR, Storkus WJ, Okada H. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Research. 67: 6451-8. PMID 17616706 DOI: 10.1158/0008-5472.CAN-06-3280  0.32
2007 Berhanu A, Huang J, Watkins SC, Okada H, Storkus WJ. Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy. Journal of Immunology (Baltimore, Md. : 1950). 178: 3400-8. PMID 17339434  0.32
2007 Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, Fellows-Mayle W, Storkus WJ, Walker PR, Salazar AM, Okada H. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. Journal of Translational Medicine. 5: 10. PMID 17295916 DOI: 10.1186/1479-5876-5-10  0.32
2006 Eguchi J, Hatano M, Nishimura F, Zhu X, Dusak JE, Sato H, Pollack IF, Storkus WJ, Okada H. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Research. 66: 5883-91. PMID 16740728 DOI: 10.1158/0008-5472.CAN-06-0363  0.32
2006 Nishimura F, Dusak JE, Eguchi J, Zhu X, Gambotto A, Storkus WJ, Okada H. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Research. 66: 4478-87. PMID 16618775 DOI: 10.1158/0008-5472.CAN-05-3825  0.32
2005 Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, Pollack IF, Hamilton RL, Storkus WJ, Okada H. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia (New York, N.Y.). 7: 717-22. PMID 16207473 DOI: 10.1593/neo.05277  0.52
2005 Warrino DE, Olson WC, Scarrow MI, D'Ambrosio-Brennan LJ, Guido RS, Da Silva DM, Kast WM, Storkus WJ. Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro Human Immunology. 66: 762-772. PMID 16112023 DOI: 10.1016/j.humimm.2005.04.006  0.52
2005 Kuwashima N, Nishimura F, Eguchi J, Sato H, Hatano M, Tsugawa T, Sakaida T, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Gambotto A, Pollack IF, Storkus WJ, Okada H. Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. Journal of Immunology (Baltimore, Md. : 1950). 175: 2730-40. PMID 16081851  0.32
2005 Muller-Berghaus J, Olson WC, Moulton RA, Knapp WT, Schadendorf D, Storkus WJ. IL-12 production by human monocyte-derived dendritic cells: Looking at the single cell Journal of Immunotherapy. 28: 306-313. PMID 16000948  0.52
2005 Macedo C, Donnenberg A, Popescu I, Reyes J, Abu-Elmagd K, Shapiro R, Zeevi A, Fung JJ, Storkus WJ, Metes D. EBV-specific memory CD8+ T cell phenotype and function in stable solid organ transplant patients. Transplant Immunology. 14: 109-16. PMID 15935301 DOI: 10.1016/j.trim.2005.02.001  0.52
2005 Eguchi J, Kuwashima N, Hatano M, Nishimura F, Dusak JE, Storkus WJ, Okada H. IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity. Journal of Immunology (Baltimore, Md. : 1950). 174: 7194-201. PMID 15905564  0.32
2005 Macedo C, Popescu I, Abu-Elmagd K, Reyes J, Shapiro R, Zeevi A, Berghaus JM, Wang LF, Lu L, Thomson AW, Storkus WJ, Fung JJ, Metes D. Augmentation of type-1 polarizing ability of monocyte-derived dendritic cells from chronically immunosuppressed organ-transplant recipients. Transplantation. 79: 451-9. PMID 15729172  0.36
2005 Herrem CJ, Tatsumi T, Olson KS, Shirai K, Finke JH, Bukowski RM, Zhou M, Richmond AL, Derweesh I, Kinch MS, Storkus WJ. Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 226-31. PMID 15671550  0.52
2004 Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, Storkus WJ, Okada H. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. Journal of Translational Medicine. 2: 40. PMID 15563374 DOI: 10.1186/1479-5876-2-40  0.32
2004 Pizzoferrato E, Liu Y, Gambotto A, Armstrong MJ, Stang MT, Gooding WE, Alber SM, Shand SH, Watkins SC, Storkus WJ, Yim JH. Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. Cancer Research. 64: 8381-8. PMID 15548708 DOI: 10.1158/0008-5472.CAN-04-2223  0.52
2004 Rayman P, Wesa AK, Richmond AL, Das T, Biswas K, Raval G, Storkus WJ, Tannenbaum C, Novick A, Bukowski R, Finke J. Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6360S-6S. PMID 15448031 DOI: 10.1158/1078-0432.CCR-050011  0.52
2004 Okada H, Tsugawa T, Sato H, Kuwashima N, Gambotto A, Okada K, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Chambers WH, Potter DM, Storkus WJ, Pollack IF. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Research. 64: 5830-8. PMID 15313927 DOI: 10.1158/0008-5472.CAN-04-0130  0.32
2004 Warrino DE, Olson WC, Knapp WT, Scarrow MI, D'Ambrosio-Brennan LJ, Guido RS, Edwards RP, Kast WM, Storkus WJ. Disease-stage variance in functional CD4+ T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes Clinical Cancer Research. 10: 3301-3308. PMID 15161683 DOI: 10.1158/1078-0432.CCR-03-0498  0.52
2003 Tatsumi T, Huang J, Gooding WE, Gambotto A, Robbins PD, Vujanovic NL, Alber SM, Watkins SC, Okada H, Storkus WJ. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Research. 63: 6378-86. PMID 14559827  0.52
2003 Popescu I, Macedo C, Zeevi A, Nellis J, Patterson KR, Logar A, Rowe D, Reyes J, Rao AS, Storkus WJ, Fung JJ, Metes D. Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 3: 1369-77. PMID 14525597 DOI: 10.1046/j.1600-6135.2003.00252.x  0.52
2003 Tatsumi T, Herrem CJ, Olson WC, Finke JH, Bukowski RM, Kinch MS, Ranieri E, Storkus WJ. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma Cancer Research. 63: 4481-4489. PMID 12907621  0.52
2003 Nakahara N, Pollack IF, Storkus WJ, Wakabayashi T, Yoshida J, Okada H. Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer Gene Therapy. 10: 549-58. PMID 12833135 DOI: 10.1038/sj.cgt.7700598  0.32
2003 Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Brusic V, Sidney J, Sette A, Logan TF, Kasamon YL, Slingluff CL, Kirkwood JM, Storkus WJ. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 947-54. PMID 12631591  0.52
2002 Tatsumi T, Gambotto A, Robbins PD, Storkus WJ. Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy. Cancer Research. 62: 5853-8. PMID 12384548  0.52
2002 Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 2851-5. PMID 12231526  0.32
2002 Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Mueller-Berghaus J, Kirkwood JM, Kwok WW, Storkus WJ. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. The Journal of Experimental Medicine. 196: 619-28. PMID 12208877 DOI: 10.1084/jem.20012142  0.52
2002 Lokshin AE, Kalinski P, Sassi RR, Mailliard RB, Müller-Berghaus J, Storkus WJ, Peng X, Marrangoni AM, Edwards RP, Gorelik E. Differential regulation of maturation and apoptosis of human monocyte-derived dendritic cells mediated by MHC class II. International Immunology. 14: 1027-37. PMID 12202400  0.52
2002 Lu G, Janjic BM, Janjic J, Whiteside TL, Storkus WJ, Vujanovic NL. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-α1β2, Fas ligand, and TNF-related apoptosis-inducing ligand Journal of Immunology. 168: 1831-1839. PMID 11823516  0.52
2001 Metes D, Storkus WJ, Zeevi A, Watkins S, Patterson K, Nellis J, Logar A, Fung JJ, Rao AS. Use of autologous dendritic cells loaded with apoptotic LCL for ex vivo generation of specific CTL from the PBMC of EBV(-) individuals. Transplantation Proceedings. 33: 441. PMID 11266900  0.36
Show low-probability matches.